Drug intelligence / Profile preview

AVT06

Development stage: Phase 3
Lead developer: Alvotech
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Ophthalmic

Overview

AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept). It binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF receptors, neovascularization, and vascular permeability. This mechanism makes it effective for treating conditions like neovascular (wet) age-related macular degeneration (AMD), macular edema, and diabetic retinopathy.

Brand names: EyleaZaltrap
Other names: afliberceptefdamrofusp alfaRBDV-IgG1 FcRBDV-IgG-1 FcRBDV-IgG 1 Fc

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)VEGFB (Vascular endothelial growth factor B)VEGFR-1 (Vascular endothelial growth factor receptor 1)

Beyond the preview

Go deeper on AVT06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVT06.

Explore the full profile